EMUC15 - Resource Centre - Search Results

178 results (Loading...)

Video Filters×
  • organe

  • access

  • procedure

  • pathology

178 Abstracts

  • Introduction & ObjectivesSince the introduction of tyrosine kinase inhibitors (TKI) in the treatment of metastatic renal cell carcinoma (RCC), prognostic of these patients was significantly approved and a few cases achieved a complete response (CR). However, the benefit of a maintenance treatment, taking into account the cost and tolerance, remains unclear. The purpose of this study is to evaluate and compare the outcome of six patients achieving a complete response on TKI after treatment discontinuation or maintenance.Material & MethodsA retrospective analysis of patients with metastatic renal cell carcinoma who obtained complete response during treatment with TKIs (sunitinib or sorafenib). From a series of 27 patients treated in our department in first line, six patients were identified in complete response on TKI according to RECIST criteria. Median age 64,5 y (range : 49-79y). All with intermediate MSKCC prognosis and received an initial nephrectomy followed by a first line treatment by Sunitinib (n=5 ) or Sorafenib (n=1) . The median number of cycles of TKI to achieve CR was 9 (range : 4 to 17 cycles).ResultsAmong the six patients who achieved CR with TKI, only one patient don’t interrupt TKI treatment after complete response (26 cycles of sunitinib ongoing to date with a persistent CR), whereas treatment was interrupted in 5 patients  at complete response (1pt) or after further cycles of the same TKI (11 cycles on average). Two of the 5 patients who stopped treatment still in CR (24 & 6 months of follow up). For the 3 other patients, local and or metastatic relapse occurred at 6, 13 & 18 months of treatment interruption. The treatment of relapsing disease was resumption of TKI (sunitinib : 2 pts, Sorafenib :1 pt) preceded by surgery in one case and resulting in a partial response for tow patients and a new complete response for one patient treated with sorafenib. Because of a significant early observed toxicity (hypertention , hypothyrreosis, fatigue , thrombopenea and hand & food syndrome ), dose of TKI was reduced after a median of 5 cycles.ConclusionsParameters associated with achievement of CR are not yet well defined, and we could not define any predictive factors to either stop or give additional cycles of TKI. As such, further research is also needed to identify factors to aid selection of patients who would be at less risk of recurrence after discontinuation of treatment. Djedi H.1, Yousfi A.1, Yahia Z.2, Bouzid K.2 7th European Multidisciplinary Meeting on Urological Cancers 1CHU Annaba, Dept. of Medical Oncology, Annaba, 2EHS P&M Curie Cancer Center, Dept. of Medical Oncology, Algiers 58737 EMUC15-0228 P151
  • Introduction & ObjectivesSince the introduction of tyrosine kinase inhibitors (TKI) in the treatment of metastatic renal cell carcinoma (RCC), prognostic of these patients was significantly approved and a few cases achieved a complete response (CR). However, the benefit of a maintenance treatment, taking into account the cost and tolerance, remains unclear. The purpose of this study is to evaluate and compare the outcome of six patients achieving a complete response on TKI after treatment discontinuation or maintenance.Material & MethodsA retrospective analysis of patients with metastatic renal cell carcinoma who obtained complete response during treatment with TKIs (sunitinib or sorafenib). From a series of 27 patients treated in our department in first line, six patients were identified in complete response on TKI according to RECIST criteria. Median age 64,5 y (range : 49-79y). All with intermediate MSKCC prognosis and received an initial nephrectomy followed by a first line treatment by Sunitinib (n=5 ) or Sorafenib (n=1) . The median number of cycles of TKI to achieve CR was 9 (range : 4 to 17 cycles).ResultsAmong the six patients who achieved CR with TKI, only one patient don’t interrupt TKI treatment after complete response (26 cycles of sunitinib ongoing to date with a persistent CR), whereas treatment was interrupted in 5 patients  at complete response (1pt) or after further cycles of the same TKI (11 cycles on average). Two of the 5 patients who stopped treatment still in CR (24 & 6 months of follow up). For the 3 other patients, local and or metastatic relapse occurred at 6, 13 & 18 months of treatment interruption. The treatment of relapsing disease was resumption of TKI (sunitinib : 2 pts, Sorafenib :1 pt) preceded by surgery in one case and resulting in a partial response for tow patients and a new complete response for one patient treated with sorafenib. Because of a significant early observed toxicity (hypertention , hypothyrreosis, fatigue , thrombopenea and hand & food syndrome ), dose of TKI was reduced after a median of 5 cycles.ConclusionsParameters associated with achievement of CR are not yet well defined, and we could not define any predictive factors to either stop or give additional cycles of TKI. As such, further research is also needed to identify factors to aid selection of patients who would be at less risk of recurrence after discontinuation of treatment. Djedi H.1, Yousfi A.1, Yahia Z.2, Bouzid K.2 7th European Multidisciplinary Meeting on Urological Cancers 1CHU Annaba, Dept. of Medical Oncology, Annaba, 2EHS P&M Curie Cancer Center, Dept. of Medical Oncology, Algiers 58737 EMUC15-0228 P151
  • Introduction & ObjectivesSince the introduction of tyrosine kinase inhibitors (TKI) in the treatment of metastatic renal cell carcinoma (RCC), prognostic of these patients was significantly approved and a few cases achieved a complete response (CR). However, the benefit of a maintenance treatment, taking into account the cost and tolerance, remains unclear. The purpose of this study is to evaluate and compare the outcome of six patients achieving a complete response on TKI after treatment discontinuation or maintenance.Material & MethodsA retrospective analysis of patients with metastatic renal cell carcinoma who obtained complete response during treatment with TKIs (sunitinib or sorafenib). From a series of 27 patients treated in our department in first line, six patients were identified in complete response on TKI according to RECIST criteria. Median age 64,5 y (range : 49-79y). All with intermediate MSKCC prognosis and received an initial nephrectomy followed by a first line treatment by Sunitinib (n=5 ) or Sorafenib (n=1) . The median number of cycles of TKI to achieve CR was 9 (range : 4 to 17 cycles).ResultsAmong the six patients who achieved CR with TKI, only one patient don’t interrupt TKI treatment after complete response (26 cycles of sunitinib ongoing to date with a persistent CR), whereas treatment was interrupted in 5 patients  at complete response (1pt) or after further cycles of the same TKI (11 cycles on average). Two of the 5 patients who stopped treatment still in CR (24 & 6 months of follow up). For the 3 other patients, local and or metastatic relapse occurred at 6, 13 & 18 months of treatment interruption. The treatment of relapsing disease was resumption of TKI (sunitinib : 2 pts, Sorafenib :1 pt) preceded by surgery in one case and resulting in a partial response for tow patients and a new complete response for one patient treated with sorafenib. Because of a significant early observed toxicity (hypertention , hypothyrreosis, fatigue , thrombopenea and hand & food syndrome ), dose of TKI was reduced after a median of 5 cycles.ConclusionsParameters associated with achievement of CR are not yet well defined, and we could not define any predictive factors to either stop or give additional cycles of TKI. As such, further research is also needed to identify factors to aid selection of patients who would be at less risk of recurrence after discontinuation of treatment. Djedi H.1, Yousfi A.1, Yahia Z.2, Bouzid K.2 7th European Multidisciplinary Meeting on Urological Cancers 1CHU Annaba, Dept. of Medical Oncology, Annaba, 2EHS P&M Curie Cancer Center, Dept. of Medical Oncology, Algiers 58737 EMUC15-0228 P151
  • Introduction & ObjectivesSince the introduction of tyrosine kinase inhibitors (TKI) in the treatment of metastatic renal cell carcinoma (RCC), prognostic of these patients was significantly approved and a few cases achieved a complete response (CR). However, the benefit of a maintenance treatment, taking into account the cost and tolerance, remains unclear. The purpose of this study is to evaluate and compare the outcome of six patients achieving a complete response on TKI after treatment discontinuation or maintenance.Material & MethodsA retrospective analysis of patients with metastatic renal cell carcinoma who obtained complete response during treatment with TKIs (sunitinib or sorafenib). From a series of 27 patients treated in our department in first line, six patients were identified in complete response on TKI according to RECIST criteria. Median age 64,5 y (range : 49-79y). All with intermediate MSKCC prognosis and received an initial nephrectomy followed by a first line treatment by Sunitinib (n=5 ) or Sorafenib (n=1) . The median number of cycles of TKI to achieve CR was 9 (range : 4 to 17 cycles).ResultsAmong the six patients who achieved CR with TKI, only one patient don’t interrupt TKI treatment after complete response (26 cycles of sunitinib ongoing to date with a persistent CR), whereas treatment was interrupted in 5 patients  at complete response (1pt) or after further cycles of the same TKI (11 cycles on average). Two of the 5 patients who stopped treatment still in CR (24 & 6 months of follow up). For the 3 other patients, local and or metastatic relapse occurred at 6, 13 & 18 months of treatment interruption. The treatment of relapsing disease was resumption of TKI (sunitinib : 2 pts, Sorafenib :1 pt) preceded by surgery in one case and resulting in a partial response for tow patients and a new complete response for one patient treated with sorafenib. Because of a significant early observed toxicity (hypertention , hypothyrreosis, fatigue , thrombopenea and hand & food syndrome ), dose of TKI was reduced after a median of 5 cycles.ConclusionsParameters associated with achievement of CR are not yet well defined, and we could not define any predictive factors to either stop or give additional cycles of TKI. As such, further research is also needed to identify factors to aid selection of patients who would be at less risk of recurrence after discontinuation of treatment. Djedi H.1, Yousfi A.1, Yahia Z.2, Bouzid K.2 7th European Multidisciplinary Meeting on Urological Cancers 1CHU Annaba, Dept. of Medical Oncology, Annaba, 2EHS P&M Curie Cancer Center, Dept. of Medical Oncology, Algiers 58737 EMUC15-0228 P151
  • Introduction & ObjectivesSince the introduction of tyrosine kinase inhibitors (TKI) in the treatment of metastatic renal cell carcinoma (RCC), prognostic of these patients was significantly approved and a few cases achieved a complete response (CR). However, the benefit of a maintenance treatment, taking into account the cost and tolerance, remains unclear. The purpose of this study is to evaluate and compare the outcome of six patients achieving a complete response on TKI after treatment discontinuation or maintenance.Material & MethodsA retrospective analysis of patients with metastatic renal cell carcinoma who obtained complete response during treatment with TKIs (sunitinib or sorafenib). From a series of 27 patients treated in our department in first line, six patients were identified in complete response on TKI according to RECIST criteria. Median age 64,5 y (range : 49-79y). All with intermediate MSKCC prognosis and received an initial nephrectomy followed by a first line treatment by Sunitinib (n=5 ) or Sorafenib (n=1) . The median number of cycles of TKI to achieve CR was 9 (range : 4 to 17 cycles).ResultsAmong the six patients who achieved CR with TKI, only one patient don’t interrupt TKI treatment after complete response (26 cycles of sunitinib ongoing to date with a persistent CR), whereas treatment was interrupted in 5 patients  at complete response (1pt) or after further cycles of the same TKI (11 cycles on average). Two of the 5 patients who stopped treatment still in CR (24 & 6 months of follow up). For the 3 other patients, local and or metastatic relapse occurred at 6, 13 & 18 months of treatment interruption. The treatment of relapsing disease was resumption of TKI (sunitinib : 2 pts, Sorafenib :1 pt) preceded by surgery in one case and resulting in a partial response for tow patients and a new complete response for one patient treated with sorafenib. Because of a significant early observed toxicity (hypertention , hypothyrreosis, fatigue , thrombopenea and hand & food syndrome ), dose of TKI was reduced after a median of 5 cycles.ConclusionsParameters associated with achievement of CR are not yet well defined, and we could not define any predictive factors to either stop or give additional cycles of TKI. As such, further research is also needed to identify factors to aid selection of patients who would be at less risk of recurrence after discontinuation of treatment. Djedi H.1, Yousfi A.1, Yahia Z.2, Bouzid K.2 7th European Multidisciplinary Meeting on Urological Cancers 1CHU Annaba, Dept. of Medical Oncology, Annaba, 2EHS P&M Curie Cancer Center, Dept. of Medical Oncology, Algiers 58737 EMUC15-0228 P151
×